Abiopharma

LifeMD Appoints Umesh Sripad as Chief Technology Officer

A New Press Release from Elicio Therapeutics

GE HealthCare Focuses on Expanding Access to Nuclear Medicine Through AI, Radiopharmaceutical and Imaging Innovations

McCormick & Company to Report 2026 Second Quarter Financial Results on June 25, 2026

Ealixir Expands Media Presence Through Affaritaliani Regional Publishing Initiative

Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/rWaldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting

LifeMD Appoints Umesh Sripad as Chief Technology Officer

Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting

Imfinzi plus Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death in EMERALD-3 Phase III trial

Net Asset Value(s)